ClinicalTrials.gg
Sign In

Drug

Anti-PD-1/Anti-VEGF Bispecific Antibody JS207 clinical trials

Also written JS207.

studies test it
7
open now
4
in phase 3
1
first study started
2022

Keep track of what changes. Save the Anti-PD-1/Anti-VEGF Bispecific Antibody JS207 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Development codes

JS207
6

Combined with it in one product

JS207 injection +docetaxel
1
JS207 injection +JS004 injection
1

Studies by the year they started

7 studies that test it; most in 2025 (2)

Studies that test Anti-PD-1/Anti-VEGF Bispecific Antibody JS207, by start year
YearStudies
20221
20231
20241
20252
20262

By phase

A phase 1/2 study counts in both.

Phase 1
3
Phase 2
4
Phase 3
1

What it is tested for

Each study’s main condition, where its own words name it.

Carcinoma, Hepatocellular
1
Triple Negative Breast Neoplasms
1

Who runs them

Industry 1 · Other 6

Shanghai Junshi Bioscience Co., Ltd. (5) · Fudan University (1) · Mabwell (Shanghai) Bioscience Co., Ltd. (1)

Often tested with

Tested in the same studies.

Docetaxel (2) · WJ47156 (1) · Toripalimab (1) · Bevacizumab (1) · JS007 (1) · Dalpiciclib (1) · Pyrotinib (1) · Trastuzumab rezetecan (1)

Studies

Open first, then newest update. How each study uses Anti-PD-1/Anti-VEGF Bispecific Antibody JS207 is read from its arms, and is right about nine times in ten.

Testing it · 7

Given in every arm · 8 — Anti-PD-1/Anti-VEGF Bispecific Antibody JS207 is usual care beside what is tested